SOURCE: BioProgress PLC

June 22, 2005 05:19 ET

BioProgress PLC announces AGM Statement

Cambridgeshire -- (MARKET WIRE) -- June 22, 2005 --


Press Release                                               22 June 2005




                                      BioProgress plc
                           ("BioProgress" or "the Company")

                                     AGM Statement

Speaking at the Company's AGM today, Richard Trevillion, the CEO and Acting Chairman of BioProgress (AIM: BPRG; NASDAQ: BPRG), will make the following comments:


  - Following the strategic review, the Directors have been reassured that the
    core strengths of the business, the intellectual property (IP) portfolio,
    remains robust and strong.



  - New financial and management controls have been put in place which   
   will result in a material reduction in cash burn.




  - The Company's focus is on commercialisation of its suite of 
    technologies.


  - The Directors will consider appropriate acquisition opportunities 
    which will enhance the value of the Company's IP portfolio.


  - Having regard to the substantial compliance cost of maintaining the 
    NASDAQ listing, the Directors will keep under close review whether 
    the maintenance of the ADR listing is in shareholders best interests.

  - The Company has settled its proceedings with Charles Tatnall.

- Ends -

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company's filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.


BioProgress plc

Richard Trevillion, CEO
Dan Farrow, FD                                  www.bioprogress.com



UK Media enquiries:
Abchurch

Samantha Robbins / Henry Harrison-Topham        Tel: +44 (0) 20 7398 7700
henry.ht@abchurch-group.com                        www.abchurch-group.com



US Investor enquiries:
Taylor Rafferty

Andrew Saunders                                   Tel: +1 212 889 4350
andrew.saunders@taylor-rafferty.com            www.taylor-rafferty.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange